XML 16 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaboration and License Agreements - Additional Information 3 (Detail) (USD $)
 3 Months Ended 6 Months Ended 1 Months Ended 3 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended 1 Months Ended
Jun. 30, 2014
Jun. 30, 2014
Dec. 31, 2013
Jan. 31, 2014
Servier [Member]
Jun. 30, 2014
Servier [Member]
Jun. 30, 2013
Servier [Member]
Jun. 30, 2014
Servier [Member]
Jun. 30, 2013
Servier [Member]
Dec. 31, 2013
Servier [Member]
Jun. 30, 2014
Servier [Member]
Second Right to Develop Collaboration [Member]
Jun. 30, 2013
Servier [Member]
Second Right to Develop Collaboration [Member]
Jun. 30, 2014
Servier [Member]
Second Right to Develop Collaboration [Member]
Jun. 30, 2013
Servier [Member]
Second Right to Develop Collaboration [Member]
Dec. 31, 2013
Servier [Member]
Second Right to Develop Collaboration [Member]
Jul. 31, 2014
Servier [Member]
Subsequent Event [Member]
Jun. 30, 2014
Servier [Member]
Maximum [Member]
Jun. 30, 2014
Servier [Member]
Maximum [Member]
Second Right to Develop Collaboration [Member]
License And Collaboration Agreements [Line Items]                                  
Collaboration agreement date             November 2011         September 2012          
Non-refundable payment             $ 20,000,000         $ 20,000,000          
Additional license grant fees 15,000,000 15,000,000                           30,000,000 65,000,000
Clinical milestone payments 5,000,000 5,000,000                           47,000,000 98,000,000
Regulatory milestone payments                               140,000,000 300,000,000
Sales milestone payments                               208,000,000 630,000,000
Expected period of development       38 months     27 months         29 months          
Recognized revenue under agreement         200,000 4,400,000 400,000 6,600,000   2,700,000 2,200,000 10,000,000 4,300,000        
Deferred revenue         400,000   400,000   900,000 19,400,000   19,400,000   9,400,000      
License option fees received                       15,000,000          
Clinical milestone payments received                   5,000,000   5,000,000          
Clinical milestone payments under agreement                                 5,000,000
Offset to research and development costs under collaboration arrangement 300,000 400,000                              
Expected development period   82 months                              
Review period   30 days                         30 days    
Milestones under agreement           0   0                  
Deferred revenue included in current liabilities 20,684,000 20,684,000 20,267,000             7,300,000   7,300,000   8,600,000      
Deferred revenue included in long-term liabilities 23,912,000 23,912,000 7,136,000             12,100,000   12,100,000   800,000      
Additional milestone payment due                             $ 5,000,000